Increased tumor necrosis factor-α, cleaved caspase 3 levels and insulin receptor substrate-1 phosphorylation in the ß1-adrenergic receptor knockout mouse.

PURPOSE: To investigate the role of ß1-adrenergic receptors on insulin like growth factor (IGF)-1 receptor signaling and apoptosis in the retina using ß1-adrenergic receptor knockout (KO) mice. METHODS: Western blotting and enzyme-linked immunosorbent assay analyses were done on whole retinal lysates from ß1-adrenergic receptor KO mice and wild-type littermates. In addition, vascular analyses of degenerate capillaries and pericyte ghosts were done on the retina of the ß1-adrenergic receptor KO mice versus littermates. RESULTS: Lack of ß1-adrenergic receptors produced a significant increase in both degenerate capillaries and pericyte ghosts. This was accompanied by an increase in cleaved caspase 3 and tumor necrosis factor α levels. IGF-1 receptor phosphorylation was not changed; however, protein kinase B (Akt) phosphorylation was significantly decreased. The decrease in Akt phosphorylation is likely caused by increased insulin receptor substrate-1 serine 307 (IRS-1(Ser307)) phosphorylation, which is inhibitory to IGF-1 receptor signaling. CONCLUSIONS: These studies further support the idea that maintenance of ß-adrenergic receptor signaling is beneficial for retinal homeostasis. Loss of ß1-adrenergic receptor signaling alters tumor necrosis factor α and apoptosis levels in the retina, as well as Akt and IGF-1 receptor phosphorylation. Since many of these same changes are observed in the diabetic retina, these data support that novel ß-adrenergic receptor agents may provide additional avenues for therapeutics.

Insulin and ß-adrenergic receptors inhibit retinal endothelial cell apoptosis through independent pathways.

Diabetic retinopathy results from altered insulin receptor signaling. Based on previous studies demonstrating an interaction between ß-adrenergic receptors and insulin signaling in hyperglycemic conditions, we hypothesized that ß-adrenergic receptor stimulation and insulin stimulation would act synergistically to inhibit one of the hallmarks of diabetic retinopathy, namely retinal endothelial cell apoptosis. To test this hypothesis, human retinal endothelial cells were grown in high glucose (25 mM) medium and treated with a ß-1-adrenergic receptor agonist (xamoterol, 10 µM) alone, insulin alone (10 nM) or xamoterol + insulin. We then assessed changes in the levels of insulin receptor, insulin-like growth factor (IGF-1) receptor, and Akt phosphorylation, as well as cleaved caspase 3. Xamoterol alone significantly decreased insulin receptor, IGF-1 receptor and Akt phosphorylation, whereas insulin alone increased insulin receptor, IGF-1 receptor, and Akt phosphorylation. Xamoterol significantly decreased apoptosis of retinal endothelial cells. This data suggests that both ß-adrenergic receptors and insulin can inhibit retinal endothelial cell apoptosis in hyperglycemic conditions, but inhibition occurs through independent pathways. These findings have implications for treatments of diabetic retinopathy.

Effects of insulin-like growth factor-1 (IGF-1) receptor signaling on rates of apoptosis in retina of dopamine beta hydroxylase (Dbh-/-) knockout mice.

We have investigated whether insulin-like growth factor-1 (IGF-1) receptor signaling alters rates of apoptosis in dopamine beta-hydroxylase (Dbh(-/-)) knockout mice. Retinal lysates from Dbh(-/-) and their heterozygote littermates (Dbh(+/-)) were used to examine the role of norepinephrine in the regulation of IGF-1 receptor signaling and apoptosis in the retina. Western blot analysis was done for protein levels of total and phosphorylated IGF-1 receptor, insulin receptor substrate-1 (IRS-1), insulin receptor substrate-2 (IRS-2), and Akt. A caspase 3 ELISA and dopamine ELISA were done on retinal lysates. To verify which regions of the retina were undergoing apoptosis, TUNEL labeling was performed. No changes in dopamine were noted between the KO and heterozygote mice. IGF-1 receptor phosphorylation was significantly decreased in Dbh(-/-) mice as compared to their heterozygote littermates (P<0.05 vs. heterozygous mice). IRS-1 protein phosphorylation was significantly decreased in KO mice (P<0.05 vs. heterozygous mice), while no significant changes were noted in IRS-2 protein phosphorylation. Akt protein phosphorylation was also reduced in the KO mice, likely leading to increased cleaved caspase 3 levels. The increase in apoptosis in the Dbh(-/-) mice occurred predominantly in the inner retina. Our results suggest that IGF-1 receptor signaling is reduced in the retina of mice with dysfunctional adrenergic receptor signaling. The data also indicate that IGF-1 receptor signaling occurs primarily through IRS-1, rather than IRS-2. The reduction in Akt phosphorylation, likely through reduced IGF-1 receptor signaling, could explain the increase in cleaved caspase 3, leading to apoptosis. These results suggest that alterations in adrenergic receptor signaling modulate IGF-1 receptor signaling, which can regulate apoptosis in the retina.

Beta-adrenergic receptor stimulation modulates iNOS protein levels through p38 and ERK1/2 signaling in human retinal endothelial cells.

Diabetic retinopathy is the leading cause of blindness in working-age adults. Recently, data has suggested that some of the pathological changes that occur in the diabetic retina may be due to increased expression of inflammatory markers. We have previously reported that human retinal endothelial cells cultured in high glucose show increased protein levels of iNOS, which were reduced when cells were pre-treated with a beta-1-adrenergic receptor agonist, xamoterol. The cellular signaling involved in this response is not known. The hypothesis of this study was that modulation of PKA activity through beta-adrenergic receptor stimulation can alter members of the mitogen-activated protein kinase (MAP kinase) family to regulate iNOS protein levels. To address this hypothesis, human retinal endothelial cells were grown in high glucose medium, treated with xamoterol, and immunoblotting and ELISA analyses were done to evaluate cellular signaling of PKA, p38 MAP kinase, and p42/p44 MAP kinase. The results indicate that treatment with xamoterol significantly reduced PKA levels in the retinal endothelial cells cultured in high glucose. This reduction in PKA was followed by decreased ratios of phosphorylated p42/p44 and p38 MAP kinases. Blockade of p42/p44 or p38 signaling could restore iNOS protein levels to those prior to xamoterol stimulation, suggesting that beta-adrenergic receptor regulates iNOS protein levels through regulation of PKA and MAP kinase signaling. These results offer new avenues for therapeutic intervention for retinal diseases that involve altered inflammatory marker expression.